A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
4.
METHOD AND APPARATUS FOR COLLECTING AND QUANTIFYING TONGUE MANIFESTATION FEATURES
A method for collecting and quantifying tongue manifestation features. The method comprises: first, automatically obtaining a high-quality tongue manifestation image that meets the requirements of traditional Chinese medicine tongue diagnosis; then, identifying from the image a tongue part of a patient, and acquiring an edge shape of a tongue surface, so as to obtain a tongue surface inspection area; performing color correction on the image by using the tongue surface inspection area, so as to subsequently perform, in the tongue surface inspection area, color and texture recognition on the tongue part; and further quantifying tongue color and tongue coating features. During remote consultation, traditional Chinese medicine physicians and/or traditional Chinese medicine practitioners can still perform tongue diagnosis, and it is possible to avoid misdiagnosis in remote diagnosis and treatment that is caused by differences in photography skills and photography device quality of patients, an insufficient capability for determining, when tongue manifestations are uploaded, whether the tongue manifestations meet the standards of traditional Chinese medicine diagnosis and treatment, etc.
A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug thereof to the subject. The glucose-6-phosphate dehydrogenase deregulated disorder can be BCL2 associated athanogene myofibrillar myopathy, amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, or Alzheimer disease.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
6.
M-CELL GP2-MEDIATED LYMPHATIC-TARGETED DRUG CARRIERS
It provides a delivery agent including Radix Astragali polysaccharide (RAP) which modulates the immune system quickly and induces anti-cancer immune responses after oral administration or aerosol administration. Fluorescently labeled RAP is shown to be efficiently delivered to mucosa of small intestine or lung by transcytosis through microfold (M) cells and directly got into contact with follicle dendritic cells (FDCs) or lung dendritic cells. In addition, it is demonstrated that glycoprotein 2 (GP2) -deficient M cells fail to transport RAP and induce immune responses, suggesting GP2 of M cells is a specific transcytosis receptor of RAP. It also provides that immunomodulatory polysaccharides could be directly transported into the mucosal immune system by M cells in a GP2-dependent way. These lymphatic-targeted macromolecules are potential delivery agent of poorly bioavailable small molecules, drugs and vaccines, or alike, via oral or aerosol drug administration.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
7.
M-CELL GP2-MEDIATED LYMPHATIC-TARGETED DRUG CARRIERS
It provides a delivery agent including Radix Astragali polysaccharide (RAP) which modulates the immune system quickly and induces anti-cancer immune responses after oral administration or aerosol administration. Fluorescently labeled RAP is shown to be efficiently delivered to mucosa of small intestine or lung by transcytosis through microfold (M) cells and directly got into contact with follicle dendritic cells (FDCs) or lung dendritic cells. In addition, it is demonstrated that glycoprotein 2 (GP2) -deficient M cells fail to transport RAP and induce immune responses, suggesting GP2 of M cells is a specific transcytosis receptor of RAP. It also provides that immunomodulatory polysaccharides could be directly transported into the mucosal immune system by M cells in a GP2-dependent way. These lymphatic-targeted macromolecules are potential delivery agent of poorly bioavailable small molecules, drugs and vaccines, or alike, via oral or aerosol drug administration.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
Taxamairin analogs useful in the treatment of cancer, pharmaceutical compositions including the same, methods of use thereof, and methods of preparation are provided. An efficient and scalable semi-synthesis of taxamairin compounds and analogs thereof from readily available commercial starting materials is provided. The synthesis involves low cost and relatively non-toxic reagents and is capable of synthesizing taxamairin A and taxamairin B and analogs thereof on multi-gram scale in yields up 12%and 21%, respectively.
C07C 69/013 - Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C07C 67/00 - Preparation of carboxylic acid esters
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A resource-independent and cost-efficient antimicrobial susceptibility testing (AST) system or apparatus that can rapidly process a large number of samples. The AST system includes a barcode-like cell sensor based on an adaptive linear filter array for implementing a fully automatic and microscope-free method for counting a very small volume of cells in samples, wherein suspended cells are concentrated into microbars with various lengths proportional to the number of cells. The AST system also includes an on-chip culture that takes much less time than standard methods, thereby realizing a low-cost and resource-independent platform for portable AST, from which results can be obtained through a portable device such as a cell phone.
23 22233 with a thickness ranging from approximately 60nm to 90 nm.The total thickness of the multi-layer thin film structure ranges from approximately 280nm to 400nm. The composite thin film has a high abrasion resistance, an excellent adhesiveness and consistent appearance color with bare metal substrate.
Provided herein are tuberculatin analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
Provided herein is a method of authenticating using peptide markers found in edible bird's nest hydrolysate. The method can be used to authenticate edible bird's nest and related products and/or distinguish between white edible bird's nest and grass edible bird's nest.
Provided is a method for authenticating animal hide gelatins using peptide markers found in animal hide gelatin hydrolysates. The method can be used to authenticate animal hide gelatins derived from donkey hide, horse hide, pig hide, and cattle hide.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
14.
METHOD AND APPARATUSES FOR A MULTI-LAYERED OR MULTIFACETED SYSTEM FOR DEACTIVATING AIRBORNE PARTICLES
An assembly to inactivate microbes in air flowing there through comprising an indirect air flow pathway, wherein the indirect air flow pathway comprises micro structures, micro cilia or meshes; wherein in the indirect air flow pathway a plurality microbial deactivation apparatuses are disposed. The plurality microbial deactivation apparatuses comprise at least one UV radiation apparatus (130), at least one physical nanometal oxide or nanometal apparatus (140), at least one negative ion apparatus (120), at least one temperature raising apparatus, at least one chemical oxidizer apparatus (150) and at least one organic antimicrobial apparatus (160). The assembly is effective in deactivation and removal of airborne particles, microbes, nanoparticles, gaseous and toxins.
Provided is a platform technology to deliver RNA therapeutics into cells. It provides a system for delivery of RNA molecules for biomedical purposes. The modular protein-based system described allows for customization of protein modules to achieve specificity in cell-targeting, thus having the ability to be optimized for treating different diseases. Examples of types of diseases that could adopt this technology for treatment include cancer, neurodegenerative diseases and viral infection.
The present invention relates to a solid-state blended polymer system that has the property of tunable lasing wavelength through adjusting the blending ratio. It can be used for health monitoring, environmental monitoring sensor and tissue imaging. Current materials do not have the broad tunable range; from blue to infra-red across the optical range. By using the same two polymers, it is possible to produce laser emitting blue to red colour. It simplifies the design, eases multi-wavelength laser sensor system integration and therefore, making the production cost-effective.
H01S 5/12 - Construction or shape of the optical resonator the resonator having a periodic structure, e.g. in distributed feedback [DFB] lasers
H01S 5/36 - Structure or shape of the active regionMaterials used for the active region comprising organic materials
C08L 61/02 - Condensation polymers of aldehydes or ketones only
C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCompositions of derivatives of such polymers
Patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
C07D 407/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
C07H 15/252 - Naphthacene radicals, e.g. daunomycins, adriamycins
C07H 17/04 - Heterocyclic radicals containing only oxygen as ring hetero atoms
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
18.
CHROMOPHORE-LABELED OLIGOSACCHARIDE MARKERS AND METHODS OF USE THEREOF
Provided herein are compositions and methods useful for the analysis and authentication of polysaccharide-rich herbs, such as Dendrobium officinale, Radix Astragali, Radix Angelica Sinensis, and related herbal products.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
HONG KONG BAPTIST UNIVERSITY (China)
UNIVERSITE DE STRASBOURG (France)
UNIVERSITE PARIS-SACLAY (France)
Inventor
Wong, Ka-Leung
Goetz, Joan
Charbonniere, Loic
Hildebrandt, Niko
Nonat, Aline
Charpentier, Cyrille
Cardoso Dos Santos, Marcelina
Cifliku, Vjona
Abstract
The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula (I) or of formula (II): wherein R is selected from H, CN group or COOH group. The phosphorescence excited-state lifetime is improved by energy transfer from surface terbium ions to core ions of the second lanthanide. The nanoparticle may further comprise a carrier molecule of analytical interest covalently attached to at least one ligand molecule.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS SUD (France)
HONG KONG BAPTIST UNIVERSITY (China)
Inventor
Wong, Ka-Leung
Goetz, Joan
Charbonniere, Loïc
Hildebrandt, Niko
Nonat, Aline
Charpentier, Cyrille
Cardoso Dos Santos, Marcelina
Cifliku, Vjona
Abstract
The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula (I) or of formula (II): wherein R is selected from H, CN group or COOH group. The phosphorescence excited-state lifetime is improved by energy transfer from surface terbium ions to core ions of the second lanthanide. The nanoparticle may further comprise a carrier molecule of analytical interest covalently attached to at least one ligand molecule.
233, or a mixture thereof comprising a metal selected from Mg or Si or AF, or a metal oxide selected from Si oxide, Ti oxide, Cr oxide, Ni oxide, Ag oxide, or Zr oxide onto the two layers of different metal oxide, and wherein the top layer has a thickness ranging from 20 nm to 200 nm. Also disclosed a substrate.
C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
Provided herein are are porphyrinato-lanthanide complexes useful as theranostic agents and methods of preparation and use thereof. The porphyrinato-lanthanide complexes are useful in the treatment and imaging of cancer.
The present disclosure relates to compounds useful in the treatment, imaging, and/or diagnosis of Epstein-Barr virus (EBV)-positive cells, such as cancer.
C07C 229/56 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho- position
C07C 15/52 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part substituted by unsaturated hydrocarbon radicals polycyclic non-condensed containing a group with formula
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.
This invention is about a novel image registration. This rigid registration is based on multiple surfaces arranged in a 3D relationship in the Cartesian coordinate system through a fiducial marker. In comparison to surface-based registration, this registration process provides more accurate registration or requires a smaller fiducial marker for the same level of registration accuracy. Moreover, this fiducial marker enables measuring coordinates in the physical domain; therefore the registration error can be measured by comparing coordinates of specific points in both physical and virtual domains. This has a potential application in comparing the imaging physical-to-image (PI) or printing image-to-physical (IP) modalities, for example, to compare the accuracies of the 3D model created by computed tomography and optical scanners. Other potential application also includes assisting a surgical navigation in a dental implant placement. The proposed fiducial marker therefore has potential development in the application of virtual reality.
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
A method and apparatus of an eye gaze tracking system using a generic camera under normal environment are disclosed. The method and apparatus can tolerate large illumination changes and feature low cost and simple operation. A method and apparatus for detecting fatigue of a user are also disclosed, comprising the steps of: localizing of the user's face; representing the user face and extracting image features therefrom; aligning the user's face and tracking the user's face; and detecting the user fatigue.
A61B 5/18 - Devices for psychotechnicsTesting reaction times for vehicle drivers
G06K 9/78 - Combination of image acquisition and recognition functions
G06K 9/46 - Extraction of features or characteristics of the image
G06K 9/62 - Methods or arrangements for recognition using electronic means
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
A skin-whitening and skin-protection composition that comprises stilbenoid (s) and/or stilbenoid-containing extract (s) obtained from Dendrobium plants, such as Dendrobium officinale and Dendrobium nobile for the management of melanogenesis, skin-darkening and skin-aging. More particularly, it relates to the usage of Dendrobium ingredients and stilbenoids to reduce the formation of melanin in melanocytes. It also relates to the usage of Dendrobium ingredients and stilbenoids to reduce the generation of reactive oxygen species and oxidative free radicals. The use of Dendrobium-derived extracts or ingredients or stilbenoids in the formulation of skin-protection, skin-whitening and/or anti-skin aging products. Compounds for use in preparation of a composition for treating, preventing, and/or delaying the progress of skin darkening or for use in skin-whitening and skin-protection which are synthesized from dihydro-resveratrol and the related synthesis method are also provided.
New anticancer and anti-obesity agents based on the cyclic peptide compounds are disclosed, and its preparation and application method for treating cancer and obesity diseases are also disclosed.
C07K 7/64 - Cyclic peptides containing only normal peptide links
C07K 7/50 - Cyclic peptides containing at least one abnormal peptide link
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
C07C 229/46 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
An anti-reflective coating comprising a topmost anti-reflective material layer comprising of sapphire or Al 2O 3, the one or more middle anti-reflective material layers, and a bottommost anti-reflective material layer deposited on top of the substrate, wherein the topmost anti-reflective material layer, the one or more middle anti-reflective material layers, and the bottommost anti-reflective material layer have alternatively higher and lower refractive indices in respect with each other. The anti-reflective coating on a substrate can form high anti-scratching.
C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
G02B 1/10 - Optical coatings produced by application to, or surface treatment of, optical elements
31.
MULTI-MODAL BIOPROBE FOR BLADDER CANCER IMAGING AND PHOTODYNAMIC THERAPY
Provided herein is a new generation of PDT agents based on porphyrin-lanthanide complexes with specific functional groups which can specifically localize on particular tumors, and their PDT processes can be monitored via NIR emission from erbium. In particular, provided herein is a multi-modal lanthanide-porphyrin PDT agent (Er-R3) that are capable of killing the bladder tumor cells selectivity via1O2 from porphyrin moiety and affording the fluorescence imaging simultaneously upon Er-R3 binding with the integrin αvβ3 isoform in bladder cancer cells.
The present invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin A and the methods to synthesize such diterpenoid derivatives. In particular, the chemical entities of such synthetic diterpene compounds in the manufacture of a medicament is for the treatment of tumors or cancers.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
33.
LANTHANIDE TOOLBOX FOR MULTI-MODAL, NON-INVASIVE TUMOR SPECIFIC THERANOSTIC PRODRUGS
Provided are theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. Also provided are synthesized europium complexes for evaluating the binding with integrin αvβ3.
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Provided are porphyrin small molecules substitutes designed and synthesized for bulk hetero junction (BHJ) organic solar cells (OSOs). Provided are synthesized materials with strong and ordered self-assembly property, leading to form bicontinuous, interpenetrating networks which are required for efficient charge separation and transport in organic solar cells. The power conversion efficiency (PCE) of the solar cells devices based on the embodiments have the highest PCE among the solution-processed BHJ solar cell based on porphyrin small molecules up to date.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A nanostructure for use in proliferation and differentiation of neural stem cells. And a method of proliferating and differentiating neural stem cells.
A method to transfer a layer of harder thin film substrate onto a softer, flexible substrate. In particular, the present invention provides a method to deposit a layer of sapphire thin film on to a softer and flexible substrate e.g. quartz, fused silica, silicon, glass, toughened glass, PET, polymers, plastics, paper and fabrics. This combination provides the hardness of sapphire thin film to softer flexible substrates.
It is provided a nucleus-permeable small-molecule inhibitor, L2P4 (where L2 is 4-(4-( Diethylamino)styryl)-N-carboxymethylpryidinium chloride and P4 is an amino acid sequence comprising CAhxYFMVFGGRrRK and they were coupled through amide bond) and synthesis thereof, which effectively targets the dimerization interface of EBNA1, a critical process for the growth of EBVs and the associated tumors. The method of treating and imaging EBV-associated cancers is also provided.
An apparatus for measuring balance ability; postural deviation, reflex and fall risk assessment of a human subject. In particular, the apparatus comprises of an elastic support mounted platform with dynamic response to external motion stimuli, an IMU and data analysis software processing device. The dynamic response from the platform also simulates realistic experience in moving over rough terrain with different topography.
The invention provides an anti-cancer composition, wherein the active ingredients thereof consist of halofuginone and sesquiterpene lactone compounds of Artemisia apiacea. The combination of halofuginone and sesquiterpene lactone compounds of Artemisia apiacea has a significant synergistic anti-cancer effect. The effect is similar and even superior to the anti-cancer effect of 5-Fu.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 36/282 - Artemisia, e.g. wormwood or sagebrush
A nano bi-material (A,B), electromagnetic spectrum shifter based on said nano bi-material (A,B) and method to produce said electromagnetic spectrum shifter using said nano bi-material (A,B) are described. In particular, nano bi-material (A,B) based electromagnetic spectrum shifter, e.g. color filters, with a wide range of transmission and color tunability and methods to produce said color filters are presented. The applications in color filters and production of color filters, reflectors and production of reflectors, and electromagnetic spectrum shifters and production of electromagnetic spectrum shifters are provided.
G02B 1/02 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of crystals, e.g. rock-salt, semiconductors
41.
SELECTIVE CANCER TRACKING ERADICATOR AND THE USES THEREOF
The present invention discloses a new modality of photodynamic therapy (PDT) through the design of the present invention's truly dual-functional-PDT and imaging-gadolinium complex (Gd-N) with a molecular formula(I), which can target cancer, cells specifically. The present invention provides a PDT drug that can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species-singlet oxygen-prior to due excitation. The present invention also provides the use of Gd-N as a tumor selective PDT photosensitizer modality.
A method to transfer a layer of harder thin film substrate onto a softer, flexible substrate. In particular, the present invention provides a method to deposit a layer of sapphire thin film on to a softer and flexible substrate e.g. PET, polymers, plastics, paper and fabrics. This combination provides the hardness of sapphire thin film to softer flexible substrates.
Method and apparatus of an eye gaze tracking system, using a generic camera under normal environment,detecting a user's iris and eye corner position associated with at least one eye iris center and at least one eye corner of the user to determine an eye vector associated with the user's gaze direction, processing the eye vector for application of a head pose estimation model arranged to model a head pose of the user so as to devise one or more final gaze points of the user. The system features low cost, simple operation and tolerates large illumination changes.
A non-invasive method for diagnosing performance of a vehicle comprising using at least one 3-axis accelerometer to perform diagnosis of the performance of an internal combustion engine including an engine power loss and one or more flaws associated with the engine mount is provided. The method is also usable for diagnosing deterioration of a suspension system of the vehicle. An apparatus comprising at least one 3-axis accelerometer be used for diagnosing performance of a vehicle is also provided. In one embodiment, the 3-axis accelerometer is embedded in a smart phone. A simple and non-invasive diagnosis of internal combustion engines is provided.
F02D 35/02 - Non-electrical control of engines, dependent on conditions exterior or interior to engines, not otherwise provided for on interior conditions
F02D 45/00 - Electrical control not provided for in groups
A composition comprising an autophagy enhancement compound is disclosed. Small molecules that are able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases are disclosed.
LONG-ACTING GEL COMPOSITION COMPRISING BLOOD SUGAR REDUCING ACTIVE COMPONENT AND CAPABLE OF CONTROLLING AND RELEASING LIPOSOME, AND PREPARATION METHOD THEREFOR
A long-acting hypodermic injection gel composition comprising insulin or exenatide and capable of controlling and releasing liposome, and a preparation method therefor. The control and release composition has very high bioavailability, and continuously performs release according to an effective drug concentration in a period and does not have an excessively high initial rapid release. The preparation method thereof comprises the following steps: mixing insulin or exenatide with lipid and a water dispersion medium, and then mixing the mixture with gel solutions such as poloxamer (such as F127 or P123) and/or a gelatin and a hyaluronic acid (HA), so as to form a protective layer on each lipid micrometer capsule and nanocapsule and deliver the drugs by means of intramuscular injection, abdominal injection or hypodermic injection, so that one injection can provide an effective period of 2 to 7 days, thereby reducing side effects of pains and stimulations.
A method of gait measurement using tri-axial accelerometer/gyro in mobile devices for monitoring and improving the physical movement of a moving subject, comprising: using a tri-axial accelerometer to formulate: a signature based on measurements of walking, heaving and lateral movements of said subject; and a quantitative indicator indicating the power level dispensed by said subject to keep balance during motion.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G01C 23/00 - Combined instruments indicating more than one navigational value, e.g. for aircraftCombined measuring devices for measuring two or more variables of movement, e.g. distance, speed or acceleration
48.
NEW TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF
Disclosed in the present invention are triptolide-nucleic acid aptamer derivatives, and a preparation method and use thereof. The structure of the triptolide-nucleic acid aptamer derivatives is as shown by formula I, wherein the definitions of R1-R7, G, A, B, M, Z and X are as described in the description. The present invention uses a nucleic acid aptamer and triptolide or modifications thereof as the starting materials, and introduces a linking group A at the C-14 hydroxyl groups, epoxy groups and five-membered ring lactones in triptolide, then connects it to a nucleic acid aptamer B, and obtains the triptolide-nucleic acid aptamer derivatives. The triptolide-nucleic acid aptamer derivatives of the present invention have the characteristics of good targeting, a high anticancer activity, low toxicity and side effects, good water solubility and high bioavailability, and the preparation method of the present invention is scientific and reasonable and has a controllable quality and good repeatability, and is thereby suitable for production.
C07J 73/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
Inventor
Zhang, Hongjie
Soejarto, Djaja D.
Fong, Harry H.S.
Abstract
This invention provides maytansinoids having improved tumor inhibition activity, In particular, the present invention pro vides a method of treatment of cancer, in particular colon cancer, using maytansinoid compounds having two fused macrocyclic rings.
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
C07J 17/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta[a]hydrophenanthrene skeleton
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A method of extracting neural stem cells from a living subject, comprising the steps of introducing magnetic nanoparticles into the subject, targeting the neural stem cells with the magnetic nanoparticles to form magnetic nanoparticle-targeted cells, isolating the magnetic nanoparticle-targeted cells, extracting the magnetic nanoparticles-targeted cells from the subject.
C07K 7/64 - Cyclic peptides containing only normal peptide links
C07K 7/50 - Cyclic peptides containing at least one abnormal peptide link
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
C07C 229/46 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
HONG KONG BAPTIST UNIVERSITY (China)
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
Inventor
Liang, Chun
Jiang, Zhihong
Wang, Ziyi
Yu, Zhiling
Wang, Jingrong
Bai, Liping
Abstract
A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
HONG KONG BAPTIST UNIVERSITY (China)
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
Inventor
Liang, Chun
Jiang, Zhihong
Wang, Ziyi
Yu, Zhiling
Wang, Jingrong
Bai, Liping
Abstract
A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
HONG KONG BAPTIST UNIVERSITY (China)
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
Inventor
Wang, Ziyi
Liang, Chun
Jiang, Zhihong
Yu, Zhiling
Wang, Jingrong
Bai, Liping
Abstract
A method of screening for an anticancer compound is provided. The method comprised the steps: (a) contacting a candidate compound with a population of cells and (b) detecting the amount of MCM subunits located in the nucleus as compared that in the cytoplasm or detecting the physical interactions of the MCM subunits.
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
The present invention discloses method s and apparatus for developing, analyzing, investigating, and advising healthcare and well-being related decisions. In particular, the present invention relates to the architecture of systems in either stand-al one or distributed/collaborative/pervasive settings, the components of the systems and their underlying processes and couplings, the computational techniques built into the method s, input data sources integrated into and output results produced and distributed by the systems, as well as the apparatus for carrying out the corresponding user interaction, data access and collection, data integration and processing, data-driven inferences and simulation, intelligent computations, decision analytics, and decision support to generating solutions to various healthcare analytics and decision-making problems. This invention al so rel ates to two working illustrations of the method s and apparatus that present the embodiment illustrations of the present invention.
A novel multilayer flexible metamaterial that can work at near infrared (NIR) regime that can be fabricated on transparent PET substrate using flip chip transfer (FCT) technique. An embodiment of the present invention also provides novel NIR metamaterial device that can be transformed into various shapes by bending the PET substrate, wherein said metamaterial device is tunable via physical manipulation of its flexible substrate with no requirement to change the material composition of the substrate. The flexibility allows the novel NIR metamaterial device to bend and stretch, which can alter the device structure. Since the resonant frequency of each device is a function of the device structure, the resonant frequency can be tuned by the bend and stretch of the substrate. Another embodiment of the present invention further provides novel tunable sensors and emitters using such flexible metamaterials and devices.
B32B 3/16 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by a face layer formed of separate pieces of material secured to a flexible backing
G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements
58.
FABRICATION OF HIGHLY FLEXIBLE NEAR-INFRARED METAMATERIALS
A method and apparatus of fabrication of a multilayer flexible metamaterial can be fabricated using flip chip transfer (FCT) technique. This technique is different from other similar techniques such as metal lift off process, which fabricates the nanostructures directly onto the flexible substrate or nanometer printing technique. It is a solution-free FCT technique using double-side optical adhesive as the intermediate transfer layer and a tri-layer metamaterial nanostructures on a rigid substrate can be transferred onto adhesive first. Another embodiment of the present invention is the fabrication method and apparatus that allows the transfer of the metamaterial from a rigid substrate such as glass, quartz and metals onto a flexible substrate such as plastic or polymer film. Thus, a flexible metamaterial can be fabricated independent of the original substrate used.
Disclosed is a composition comprising compounds of formulae (I-V) or the salts thereof and the pharmaceutically-acceptable carrier, which is used to treat autophagy-associated diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. Additionally, a method of treating these diseases, as well as the use of said compounds in preparing composition are also disclosed.
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
60.
AUTOMATIC AND SEMI-AUTOMATIC IMAGE CLASSIFICATION, ANNOTATION AND TAGGING THROUGH THE USE OF IMAGE ACQUISITION PARAMETERS AND METADATA
A method for characterizing image contents automatically or semi-automatically using image acquisition parameters and metadata is presented. The method establishes probabilistic and deterministic relationships between different types of metadata and the semantic attributes and contents of images. It furnishes a mechanism that enables the automatic and semi-automatic classification, annotation, tagging, indexing, searching, identification or retrieval of images based on their contents, semantic properties and metadata characteristics. The method uses, but is not limited to, image capture metadata such as focal length, exposure time, relative aperture, flash information, ISO setting, angle of view, subject distance, timestamp, GPS information as well as other forms of metadata, including but not limited to, captions, keywords, headings, tags, comments, remarks, titles which may be automatically, semi-automatically, or manually generated. The present invention can be applied to image databases, web searching, personal search, community search, broad-based or vertical search engines for internet, intranet, extranet or other usages.
patents
